Log in

Relevant bibliographies by topics / M. P. Möller Organ Company

Contents

Journal articles
Books

Academic literature on the topic 'M. P. Möller Organ Company'

Author: Grafiati

Published: 29 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'M. P. Möller Organ Company.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "M. P. Möller Organ Company"

1

Takase, Y., H. Doi, T. Iwasaki, et al. "THU0285 ANALYSIS OF THE RELATIONSHIP BETWEEN ORGAN DAMAGE AND QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 369.2–370. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3027.

Full text

Abstract:

Background:Systemic lupus erythematosus (SLE) is an autoimmune disease that can not only cause systemic symptoms, such as fever and arthritis, but can also damage important organs, such as those of the central nervous system and the kidneys. Prevention of irreversible organ damage is important for better prognosis [1]. Additionally, the importance of maintaining the quality of life (QOL) of patients has recently been emphasized. However, only a few studies have examined the relationship between irreversible organ damage and patient QOL.Objectives:To assess the relationship between organ damage

APA, Harvard, Vancouver, ISO, and other styles

2

Kawamura, Koji, Junya Kanda, Sachiko Seo, et al. "Difference in the Donor Selection Priority in Allogeneic Hematopoietic Stem Cell Transplantation According to Patient Age." Blood 134, Supplement_1 (2019): 46. http://dx.doi.org/10.1182/blood-2019-125032.

Full text

Abstract:

Introduction: Selection of an appropriate donor is important for the success of allogeneic hematopoietic stem cell transplantation (allo-HCT). In general, an HLA-matched related donor (M-RD) and an HLA-matched unrelated donor (M-UD) are considered to be the first and second preferred donors in allo-HCT. On the other hand, the most suitable alternative donor remains unclear, when M-RD and M-UD are unavailable. In addition, the information on a suitable donor selection for elderly patients are limited. We hypothesized that the patient age might change the donor selection priority in allo-HCT, be

APA, Harvard, Vancouver, ISO, and other styles

3

Dispenzieri, Angela, Eftathios Kastritis, Ashutosh D. Wechalekar, et al. "Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)." Blood 134, Supplement_1 (2019): 139. http://dx.doi.org/10.1182/blood-2019-124409.

Full text

Abstract:

Background Systemic AL amyloidosis is a clonal plasma cell disorder in which amyloid fibrils are deposited in tissues and organs, leading to multi-system organ dysfunction. The most frequently involved organs are the heart and kidney (individually or together), with advanced cardiac involvement conferring particularly poor outcomes. Achievement of hematologic response and improved organ function result in better outcomes. There are currently no approved treatments for AL amyloidosis; multiple myeloma (MM) treatment strategies are used for these pts. Active, tolerable treatment options specific

APA, Harvard, Vancouver, ISO, and other styles

4

Hamilton, Betty K., Lisa A. Rybicki, Taylor Lucas, et al. "Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation." Blood 138, Supplement 1 (2021): 99. http://dx.doi.org/10.1182/blood-2021-149686.

Full text

Abstract:

Abstract Background: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). The combination of tacrolimus (Tac) and methotrexate (MTX) is a standard regimen for GVHD prophylaxis; however, it is associated with several toxicities and patients are often not able to complete the full MTX regimen. The combination of Tac, reduced dose ("mini")-MTX, and mycophenolate mofetil (MMF) has been investigated with a well-tolerated toxicity profile and low incidence of GVHD, although comparison with standard dose MTX has n

APA, Harvard, Vancouver, ISO, and other styles

5

Paolino, S., E. Gotelli, A. Casabella, et al. "SAT0337 EVALUATION OF BODY COMPOSITION AND BONE STATUS ACCORDING TO MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS PATIENTS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 1114.3–1114. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5693.

Full text

Abstract:

Background:Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease, characterized by autoimmune inflammatory microvascular damage with progressive loss of capillaries, fibrosis and ischemia of skin and internal organs. (1) Nailfold videocapillaroscopy (NVC) is a safe toll for early diagnosis of SSc, it identify morphological changes of vessel that are predictive for clinical disease progression and organ involvement.(2) About clinical complication the loss of bone mass and body composition abnormalities, particularly muscle mass and strength loss (sarcopenia), are recognized

APA, Harvard, Vancouver, ISO, and other styles

6

Zamir, Itai, Tamir Shragai, Svetlana Trestman, et al. "Multiple Myeloma Oligosecretory Relapse, a Non-Negligible Phenomenon. Frequency, Clinical Characteristics and Outcomes in a Single Center." Blood 138, Supplement 1 (2021): 3772. http://dx.doi.org/10.1182/blood-2021-151255.

Full text

Abstract:

Abstract Introduction: Multiple myeloma (MM) is malignancy of plasma cells, which secrete monoclonal antibodies that are detectable in the patient's (pt) serum and/or urine. Infrequently, MM may present as an oligosecretory disease, where monoclonal protein (M-protein) and involved free light chain (iFLC) are either not detected (=non-secretory) or are both below the threshold for measurable disease (=oligosecretory) as defined by International Myeloma Working Group (IMWG). The incidence of non-secretory MM at presentation has been estimated at 1-2% [Chawla, Eur J Haematol 2015], yet data rega

APA, Harvard, Vancouver, ISO, and other styles

7

Watson, Crystal, Hemanth Gadikota, Arie Barlev, and Rachel Beckerman. "An Evidence Review of the Long-Term Consequences Associated with Components of the CHOP Chemotherapy Regimen in Transplant Recipients." Blood 138, Supplement 1 (2021): 4586. http://dx.doi.org/10.1182/blood-2021-147242.

Full text

Abstract:

Abstract Introduction: Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV + PTLD) can be an aggressive, often deadly disease without any approved treatments. Current available treatments for EBV + PTLD may include cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). However, the long-term consequences of CHOP are poorly understood in immunocompromised transplant patients with cancer who may have different outcomes than immunocompetent cancer patients. This study reviewed and described the evidence for the long-term consequences associated with components o

APA, Harvard, Vancouver, ISO, and other styles

8

Comenzo, Raymond, Giovanni Palladini, Efstathios Kastritis, et al. "Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study." Blood 138, Supplement 1 (2021): 159. http://dx.doi.org/10.1182/blood-2021-146820.

Full text

Abstract:

Abstract Introduction: Light chain (AL) amyloidosis is a plasma cell disease characterized by the deposition of insoluble amyloid fibrils into organs leading to organ dysfunction and death. The analysis at 6 and 12 months of the ANDROMEDA study (NCT03201965) showed that the addition of subcutaneous (SC) daratumumab to the standard of care combination of bortezomib, cyclophosphamide, and dexamethasone (VCd) was superior to VCd alone, with higher rates of hematologic complete response (CR) and an acceptable safety profile. Based on these findings daratumumab with VCd (D-VCd) was approved for new

APA, Harvard, Vancouver, ISO, and other styles

9

Bouchra, Ait El Aouad, Fadli Anas, Aderdour Tarik, Talha Abdelhak, Benkirane Rachid, and Benahia Hamid. "Investigating salt tolerance in citrus rootstocks under greenhouse conditions using growth and biochemical indicators." Biolife 3, no. 4 (2022): 820–26. https://doi.org/10.5281/zenodo.7306481.

Full text

Abstract:

  <strong>ABSTRACT</strong> Citrus is ranked among the most sensitive crops to salinity. This constrainst affects plant morpho-physiology and may lead to yield declines. To assess the effects of salinity on some physiological and biochemical traits, an in vivo screening test was performed under controled saline conditions using different citrus rootstocks i.e. citrumelo 57-98-502, Swingle citrumelo F9-22-55 (80-11), citrumelo 57-98-506, Swingle citrumelo 74-1, citrumelo Winter Haven B2, Carrizo citrange 28608, Troyer citrange C35B6A11, Troyer citrange B2 31655, citrumelo 4475 B2G3, citrum

APA, Harvard, Vancouver, ISO, and other styles

10

Daver, Naval, Sreyashi Basu, Guillermo Garcia-Manero, et al. "Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response." Blood 136, Supplement 1 (2020): 43–45. http://dx.doi.org/10.1182/blood-2020-142824.

Full text

Abstract:

Background: Blockade of PD-1/PD-L1 pathways enhances anti-leukemic responses in pre-clinical studies. PD1 inhibition alone had limited clinical activity in AML. CLTA4 inhibition demonstrated encouraging single-agent CR's in postASCT patients (pts), especially for extra-medullary (EMD) relapses (Davis M et al, NEJM 2016). AZA+Nivo up-regulated CTLA4 on bone marrow (BM) CD8 cells in both responders (R) and non-responders (NR) on treatment (Daver N, et al, Cancer Discovery 2019), suggesting a triplet of AZA+Nivo+Ipi may abrogate PD-1 mediated resistance. Methods: Pts were eligible for the AZA+Niv

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "M. P. Möller Organ Company"

1

Glück, Sebastian M., Rollo F. Maitland, Paul R. Marchesano, Irvin J. Morgan, Alexander Russell, and Owen Barbara. Organ Historical Society Philadelphia 2016: Diamond jubilee commemorative anthology. OHS Press, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Doesburg, Cor L. Orgels bij de omroep in Nederland: Historie van orgels bij de omroepen in Nederland in orgelhistorisch perspectief, over besluitvorming bij de aanschaf, over het gebruik van orgelmuziek in de uitzendingen, over organisten en orgelbouwers. Strengholt, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!